Transwell-grown HepG2 cell monolayers as in vitro permeability model to study drug-drug or drug-food interactions

Journal of Medicinal Food

Volumn 14, Issue 1-2, 2011, Pages 135-139

  Berginc, Katja ^a   Kristl, Albin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

aged garlic extract; darunavir; multidrug resistance associated protein 2; P glycoprotein; saquinavir

Indexed keywords

AGED GARLIC EXTRACT; DARUNAVIR; DIGOXIN; GARLIC EXTRACT; GLYCOPROTEIN P; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; PLANT MEDICINAL PRODUCT; ROSUVASTATIN; SAQUINAVIR; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG INTERACTION; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIVER; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; TRANSPORT KINETICS;

BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; GARLIC; HEP G2 CELLS; HIV PROTEASE INHIBITORS; HUMANS; LIVER; MODELS, BIOLOGICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PERMEABILITY; PLANT EXTRACTS; SAQUINAVIR; SULFONAMIDES;

ALLIUM SATIVUM; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79952085910     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2010.0041     Document Type: Article

References (19)

1. Brandon EFA, Raap CD, Meijerman I, Beijnen JH, Schellens JHM: An update on in vitro methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 2003;189:233-246. (Pubitemid 36677534)
2. Hariparsad N, Sane RS, Strom SC, Desai PB: In vitro methods in human drug biotransformation research: implications for cancer chemotherapy. Toxicol In Vitro 2006;20:135-153.
3. Alexandre E, David P, Viollon C, Wolf P, Jaeck D, Azimzadeh A, Nicod L, Boudjema K, Richert L: Expression of cytochromes P-450 2E1, 3A4 and 1A1/1A2 in growing and confluent human HepG2 hepatoma cells - effect of ethanol. Toxicol In Vitro 1999;13:427-435.
4. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J: Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007;35:1333-1340. (Pubitemid 47121774)
5. Berginc K, Žakelj S, Kristl A: In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur J Nutr 2010;49:373-384.
6. Lee LS, Andrade ASA, Flexner C: Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Curr Infect Dis Rep 2006;43:1052-1059.
7. Yeh YY, Liu L: Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. J Nutr 2001;131(3 Suppl):989S-993S.
8. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J: The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234-238. (Pubitemid 34028358)
9. Fugh-Berman A, Ernst E: Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001;52:587-595.
10. Madara JL, Stafford J, Dharmsathaporn K, Carlson S: Structural analysis of human intestinal epithelial cell line. Gastroenterology 1987;92:1133-1145. (Pubitemid 17055900)
11. Chambard M, Gabrion J, Mauchamp J: Influence of collagen gel on the orientation of epithelial cell polarity: follicle formation from isolated thyroid cells and from performed monolayers. J Cell Biol 1981;91:157-166. (Pubitemid 12252775)
12. Lambert GP, Gisolfi CV, Berg DJ, Moseley PL, Oberley LW, Kregel KC: Hyperthermia-induced intestinal permeability and the role of oxidative and nitrosative stress. J Appl Physiol 2002;92:1750-1761. (Pubitemid 34670935)
13. Hawkins BT, Ocheltree SM, Norwood KM, Egleton RD: Decreased blood-brain barrier permeability to fluorescein in streptozotocin- treated rats. Neurosci Lett 2007;411:1-5. (Pubitemid 44751936)
14. Berginc K, Žakelj S, Uršič D, Kristl A: Aged garlic extract stimulates P-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol Pharm Bull 2009;32:694-699.
15. Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, Raoof A: Absorption, metabolism and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos 2009;37:809-820.
16. Wu CY, Benet LZ: Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a Biopharmaceutical Drug Disposition Classification System. Pharm Res 2005;22:11-23.
17. Katsura T, Inui KI: Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab Pharmacokinet 2003;18:1-15.
18. Wang E, Casciano CN, Clement RP, Johnson WW: HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001;18:800-806. (Pubitemid 32783516)
19. Heimeur A, Conseil G, Deeley RG, Cole SPC: The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 2004;5:21-53. (Pubitemid 38294344)